<html xmlns="http://www.w3.org/1999/xhtml" xmlns="http://www.w3.org/1999/xhtml">
 <head xmlns="http://www.w3.org/1999/xhtml">
 <title xmlns="http://www.w3.org/1999/xhtml"></title>
 </head>
 <body xmlns="http://www.w3.org/1999/xhtml">
 
 CEL-SCI Corporation (NYSE MKT: <a class="ticker" href="/stock/cvm#NYSE MKT">CVM</a>) announces that it has 
 received the official minutes from its February 8, 2017 meeting with the 
 U.S. Food and Drug Administration (FDA) in regards to the partial 
 clinical hold placed on the Phase 3 head and neck cancer study with 
 CEL-SCI's investigational drug Multikine* (Leukocyte Interleukin, 
 Injection) on September 26, 2016. Pursuant to this partial clinical 
 hold, patients currently receiving study treatments can continue to 
 receive treatment at the discretion of their physicians and with their 
 consent, and patients already enrolled in the study will continue to be 
 followed. 928 patients are enrolled in this study.
 
 
 The purpose of the Type A (face-to-face) meeting with the FDA was to 
 allow an open and frank discussion of the clinical hold issues raised by 
 the FDA and to secure the FDA's input and clarification on how to 
 address the partial hold issues.
 
 
 The Action Items for CEL-SCI to pursue per the minutes from the FDA are 
 the following:
 
 
 1) Provide an updated Investigator's Brochure and current procedures for 
 compliance with requirements under 21 CFR 312 Subpart D to address the 
 partial clinical hold.
 
 
 2) Provide a list of major protocol deviations, which CEL-SCI believes 
 will affect study results, and provide a plan to identify major protocol 
 deviations across all patients enrolled in the Phase 3 protocol.
 
 
 CEL-SCI is working diligently on responding to all action items.
 
 
 CEL-SCI is giving the FDA issues top priority. It is our belief that 
 addressing the Action Items listed above will support a favorable 
 decision by the FDA to lift the partial clinical hold. While we think 
 that we have understood the Action Items, it is possible that we have 
 not understood all issues involved. All of our work is subject to the 
 FDA&#39;s review of our submission upon its completion and may or may not 
 result in the lifting of the partial clinical hold.
 
 
 About CEL-SCI Corporation
 
 
 CEL-SCI&#39;s work is focused on finding the best way to activate the immune 
 system to fight cancer and infectious diseases. Its lead investigational 
 immunotherapy, Multikine (Leukocyte Interleukin, Injection), is 
 currently being studied in a pivotal Phase 3 clinical trial as a 
 potential neoadjuvant treatment for patients with squamous cell 
 carcinoma of the head and neck. Subject to the partial clinical hold, 
 the study was designed with the objective that, if the study endpoint, 
 which is an improvement in overall survival of the subjects treated with 
 the Multikine treatment regimen plus the current standard of care (SOC) 
 as compared to subjects treated with the current SOC only, is satisfied, 
 the study results will be used to support applications that the Company 
 plans to submit to regulatory agencies in order to seek commercial 
 marketing approvals for Multikine in major markets around the world. 
 Additional clinical indications for Multikine that are being 
 investigated include the treatment of cervical dysplasia in HIV/HPV 
 co-infected women, and the treatment of peri-anal warts in HIV/HPV 
 co-infected men and women. A Phase 1 trial of the former indication 
 (treatment of cervical dysplasia in HIV/HPV co-infected women) has been 
 completed at the University of Maryland. The latter indication 
 (treatment of peri-anal warts in HIV/HPV co-infected men and women) is 
 being studied in a Phase 1 trial at the University of California, San 
 Francisco. CEL-SCI has patents on Multikine from the US, Europe, China, 
 and Japan.
 
 
 CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand Epitope 
 Antigen Presentation System) technology for the potential treatment of 
 pandemic influenza in hospitalized patients and as a potential vaccine 
 for the treatment of rheumatoid arthritis.
 
 
 The Company has operations in Vienna, Virginia, and in/near Baltimore, 
 Maryland.
 
 
 Forward-Looking Statements
 
 
 This press release contains forward-looking statements within the 
 meaning of Section 27A of the Securities Act of 1933, as amended, and 
 Section 21E of the Securities Exchange Act of 1934, as amended. When 
 used in this press release, the words &#34;intends,&#34; &#34;believes,&#34; 
 &#34;anticipated,&#34; &#34;plans&#34; and &#34;expects,&#34; and similar expressions, are 
 intended to identify forward-looking statements. Such statements are 
 subject to risks and uncertainties that could cause actual results to 
 differ materially from those projected. Such statements include, but are 
 not limited to, statements about the terms, expected proceeds, use of 
 proceeds and closing of the offering. Factors that could cause or 
 contribute to such differences include, an inability to duplicate the 
 clinical results demonstrated in clinical studies, timely development of 
 any potential products that can be shown to be safe and effective, 
 receiving necessary regulatory approvals, difficulties in manufacturing 
 any of the Company&#39;s potential products, inability to raise the 
 necessary capital and the risk factors set forth from time to time in 
 CEL-SCI&#39;s filings with the Securities and Exchange Commission, including 
 but not limited to its report on Form 10-K and 10-K/A for the year ended 
 September 30, 2016. The Company undertakes no obligation to publicly 
 release the result of any revision to these forward-looking statements 
 which may be made to reflect the events or circumstances after the date 
 hereof or to reflect the occurrence of unanticipated events.
 
 
 * Multikine (Leukocyte Interleukin, Injection) is the trademark that 
 CEL-SCI has registered for this investigational therapy, and this 
 proprietary name is subject to FDA review in connection with the 
 Company&#39;s future anticipated regulatory submission for approval. 
 Multikine has not been licensed or approved for sale, barter or exchange 
 by the FDA or any other regulatory agency. Similarly, its safety or 
 efficacy has not been established for any use. Moreover, no definitive 
 conclusions can be drawn from the early-phase, clinical-trials data 
 involving the investigational therapy Multikine. Further research is 
 required, and early-phase clinical trial results must be confirmed in 
 the Phase 3 clinical trial of this investigational therapy that is in 
 progress and that is currently subject to a clinical hold on enrollment 
 of additional new patients.
 
 <img xmlns="http://www.w3.org/1999/xhtml" alt="" src="http://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20170306005667r1&amp;sid=benz2&amp;distro=nx&amp;lang=en"></img>View source version on businesswire.com: <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.businesswire.com/news/home/20170306005667/en/" rel="nofollow" rel="nofollow">http://www.businesswire.com/news/home/20170306005667/en/</a></body></html>

Press Releases

CEL-SCI Gives Update on Partial Clinical Hold on Phase 3 Head and Neck Cancer Study with Multikine - CEL-SCI (AMEX:CVM)

CEL-SCI

CEL-SCI Gives Update on Partial Clinical Hold on Phase 3 Head and Neck Cancer Study with Multikine

TYO:6723


Renesas Electronics Corporation (TSE: 6723), a premier supplier of advanced semiconductor solutions, today announced the consolidated financial forecasts for the six months ending June 30, 2024.


Renesas Electronics

Renesas Announces Consolidated Forecasts

AHKSY

TYO:3407


Asahi Kasei announced today that it will construct an integrated plant in Ontario, Canada for the base film manufacturing and coating of Hipore™ wet-process lithium-ion battery (LIB) separator1. In relation to

Asahi Kasei to Construct a Lithium-ion Battery Separator Plant in Canada


Renesas Electronics Corporation (TSE:6723) today announced consolidated financial results in accordance with IFRS for the three months ended March 31, 2024.


Summary of Consolidated Financial Results (Note

Renesas Reports Financial Results for the First Quarter Ended March 31, 2024


Orion Group (&#34;Orion&#34;), a commercial and industrial field services company backed by Alpine Investors (&#34;Alpine&#34;), announced today that it has partnered with Academy Locksmith (&#34;Academy&#34;). Academy provides mechanical and

Orion Group&#39;s Facilities Maintenance Business Enters Lock, Door, Safe, and Access Control Market Through Partnership with Academy Locksmith


Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of HashiCorp Inc. (NASDAQ:HCP) to IBM for $35.00 per share in cash is fair to HashiCorp shareholders.


Halper Sadeh encourages HashiCorp

HCP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of HashiCorp Inc. Is Fair to Shareholders


Highlights for the first quarter of 2024 as compared to the first quarter of 2023:



Revenue increased by 20%.



Operating income increased by 42%.



Net income attributable to the Company increased by 34%.



The